These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36212998)

  • 21. Comparative Efficacy and Safety of Therapies in IgA Nephropathy: A Network Meta-analysis of Randomized Controlled Trials.
    Yang P; Zou H; Xiao B; Xu G
    Kidney Int Rep; 2018 Jul; 3(4):794-803. PubMed ID: 29989013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Agents in IgA Nephropathy: An Update Network Meta-Analysis.
    Yang P; Wang Q; Xie C; Xu G; Wu Q
    Kidney Blood Press Res; 2018; 43(6):1890-1897. PubMed ID: 30566932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
    Ji Y; Yang K; Xiao B; Lin J; Zhao Q; Bhuva MS; Yang H
    J Cell Biochem; 2019 Mar; 120(3):3689-3695. PubMed ID: 30270542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of combined angiotensin II receptor blocker with tripterygium glycosides on diabetic nephropathy: A protocol for meta-analysis.
    Ma CE; Yu P; Wei W; Chen XQ
    Medicine (Baltimore); 2021 Jun; 100(22):e25991. PubMed ID: 34087843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials.
    Zhao Y; Fan H; Bao BY
    Iran J Public Health; 2019 Sep; 48(9):1577-1588. PubMed ID: 31700813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and prognostic significance of C1q deposition in IgAN patients-a retrospective study.
    Tian S; Yang X; Luo J; Guo H
    Int Immunopharmacol; 2020 Nov; 88():106896. PubMed ID: 33182045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
    Li P; Chen YZ; Lin HL; Ni ZH; Zhan YL; Wang R; Yang HT; Fang JA; Wang NS; Li WG; Sun XF; Chen XM
    Trials; 2017 Apr; 18(1):170. PubMed ID: 28395659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of tripterygium glycosides for Graves ophthalmopathy: A systematic review and meta-analysis.
    Liu X; Gao C; Liu X; Gao T
    Medicine (Baltimore); 2019 Dec; 98(50):e18242. PubMed ID: 31852090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effectiveness and Safety of
    Jia Q; Guo J; Cai Y; Huang W; Zhu Z; Xia C; Guo K; Shang H; Liu Y; Liu W
    Evid Based Complement Alternat Med; 2022; 2022():9730753. PubMed ID: 36248420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral adsorbents for preventing or delaying the progression of chronic kidney disease.
    Wu HM; Sun HJ; Wang F; Yang M; Dong BR; Liu GJ
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007861. PubMed ID: 25317905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunosuppressants or corticosteroids compared with supportive therapy: a systematic review and meta-analysis on the efficacy and safety for IgA nephropathy treatment.
    Feng Q; Xiong Y; Wang J; Feng L
    Ann Transl Med; 2022 Mar; 10(6):355. PubMed ID: 35433980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.
    Vaz de Castro PAS; Bitencourt L; Pereira BWS; Lima AQR; Hermida HS; Moreira Neto CR; Mestriner MD; Simões E Silva AC
    Pediatr Nephrol; 2022 Mar; 37(3):499-508. PubMed ID: 34686915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of inhibitors of renin-angiotensin-aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function.
    Moriyama T; Nakayama K; Ochi A; Amemiya N; Tsuruta Y; Kojima C; Itabashi M; Takei T; Uchida K; Nitta K
    Clin Exp Nephrol; 2012 Apr; 16(2):231-7. PubMed ID: 22038185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rheum officinale (a traditional Chinese medicine) for chronic kidney disease.
    Wang H; Song H; Yue J; Li J; Hou YB; Deng JL
    Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD008000. PubMed ID: 22786510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis of Tripterygium wilfordii Hook F in the immunosuppressive treatment of IgA nephropathy.
    Chen YZ; Gao Q; Zhao XZ; Chen XM; Zhang F; Chen J; Xu CG; Sun LL; Mei CL
    Intern Med; 2010; 49(19):2049-55. PubMed ID: 20930429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy of seven Chinese patent medicines for early diabetic kidney disease: A Bayesian network meta-analysis.
    Zhao J; Ai J; Mo C; Shi W; Meng L
    Complement Ther Med; 2022 Aug; 67():102831. PubMed ID: 35398481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of Shenkang injection as adjuvant therapy in patients with diabetic nephropathy: A protocol for systematic review and meta-analysis.
    Wang Y; Li M; Li C; Xu S; Wu J; Zhang G; Cai Y
    Medicine (Baltimore); 2020 Dec; 99(52):e23821. PubMed ID: 33350769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy, safety, and cost of nine Chinese patent medicines combined with ACEI/ARB in the treatment of early diabetic kidney disease: A network meta-analysis.
    Liu J; Zhang X; Xu G
    Front Pharmacol; 2022; 13():939488. PubMed ID: 36071841
    [No Abstract]   [Full Text] [Related]  

  • 39. [Network Meta-analysis of efficacy of Chinese patent medicine in treatment of inflammatory response in diabetic nephropathy].
    Shi RY; Zhang LQ; Zhang KX; Li QR; Wang XX; Yang K
    Zhongguo Zhong Yao Za Zhi; 2023 Jul; 48(13):3633-3649. PubMed ID: 37474996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pilot and comparative study between pathological and serological levels of immunoglobulin and complement among three kinds of primary glomerulonephritis.
    Dong J; Peng T; Gao J; Jia X; Yan G; Wang Y
    BMC Immunol; 2018 Jun; 19(1):18. PubMed ID: 29925312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.